8 research outputs found

    Considering the case for an antidepressant drug trial involving temporary deception: a qualitative enquiry of potential participants

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Systematic reviews of randomised placebo controlled trials of antidepressant medication show small and decreasing differences between pharmacological and placebo arms. In part this finding may relate to methodological problems with conventional trial designs, including their assumption of additivity between drug and placebo trial arms. Balanced placebo designs, which include elements of deception, may address the additivity question, but pose substantial ethical and pragmatic problems. This study aimed to ascertain views of potential study participants of the ethics and pragmatics of various balanced placebo designs, in order to inform the design of future antidepressant drug trials.</p> <p>Methods</p> <p>A qualitative approach was employed to explore the perspectives of general practitioners, psychiatrists, and patients with experience of depression. The doctors were chosen via purposive sampling, while patients were recruited through participating general practitioners. Three focus groups and 12 in-depth interviews were conducted. A vignette-based topic guide invited views on three deceptive strategies: post hoc, authorised and minimised deception. The focus groups and interviews were tape-recorded and transcribed. Transcripts were analysed thematically using Framework.</p> <p>Results</p> <p>Deception in non-research situations was typically perceived as acceptable within specific parameters. All participants could see the potential utility of introducing deception into trial designs, however views on the acceptability of deception within antidepressant drug trials varied substantially. Authorized deception was the most commonly accepted strategy, though some thought this would reduce the effectiveness of the design because participants would correctly guess the deceptive element. The major issues that affected views about the acceptability of deception studies were the welfare and capacity of patients, practicalities of trial design, and the question of trust.</p> <p>Conclusion</p> <p>There is a trade-off between pragmatic and ethical responses to the question of whether, and under what circumstances, elements of deception could be introduced into antidepressant drug trials. Ensuring adequate ethical safeguards within balanced placebo designs is likely to diminish their ability to address the crucial issue of additivity. The balanced placebo designs considered in this study are unlikely to be feasible in future trials of antidepressant medication. However there remains an urgent need to improve the quality of antidepressant drug trials.</p

    3D analysis of cut marks using a new geometric morphometric methodological approach

    No full text
    The arrival of new methodological approaches to study microscopic qualities in cut mark morphology has been a major improvement in our understanding of butchering activities. Micro-morphological differences can be detected in multiple different taphonomic alterations on bone cortical surfaces that can later be used to compare different trace mark types. Through this, we can generate studies that are able to diagnose the specific taphonomic agents and activities that produce said traces that can be found on osteological surfaces. This paper presents experimental data that have been studied using micro-photogrammetry and geometric morphometrics, successfully distinguishing morphological differences in cut marks produced by different lithic tool types as well as different raw materials. The statistical results and methodologies presented here can later be applied to archaeological sites; aiding in our understanding of raw material exploitation, tool production as well as the different butchering activities that are present in faunal assemblages
    corecore